Business
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided financial results for fiscal year 2024 and provided a corporate update.
About this update from Tuhura Biosciences, Inc.
[{"type":"text","content":"Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided financial results for fiscal year 2024 and provided a corporate update.","length":353,"tagName":"p"},{"type":"text","content":""2024 was a transformative year for TuHURA. We became a NASDAQ-listed Company, raised capital to meet FDA's manufacturing requirements to initiate our Phase 3 program anticipated for Q2 as forecasted and entered into a definitive agreement for, what we believe, is a best-in-class VISTA inhibiting antibody adding a Phase 2 program in AML to our development pipeline," commented James Bianco, President and CEO of TuHURA. "As we advance our late stage clinical programs in 2025 with the goal of completing enrollment in our Phase 3 trial next year, we are also making significant progress in the development of the first novel class of non-tumor targeting Antibody Drug or Antibody Peptide Conjugates that are demonstrating the potential ability to remove the immunosuppressive functions of key cellular populations that create an immunologic sanctuary for tumors leading to acquired resistance to cancer immunotherapies."","length":951,"tagName":"p"},{"type":"text","content":"2024 Highlights ","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Successful SPA agreement with FDA","length":33,"tagName":"p"}]},{"val":[{"type"...